Arrhythmogenic Cardiomyopathy
An evidence-based overview of arrhythmogenic cardiomyopathy, ventricular arrhythmia risk, family screening and long-term care.
Arrhythmogenic cardiomyopathy is a heart-muscle disorder in which scar and structural change can create a substrate for ventricular arrhythmias. It may affect the right ventricle, the left ventricle or both. Genetic factors are common, although the clinical expression varies considerably within families.
Diagnosis and Risk Assessment
Assessment may combine ECG, rhythm monitoring, echocardiography, cardiac MRI, exercise history, family history and genetic evaluation. No single test establishes every case. Ventricular function, documented arrhythmias, unexplained fainting, genetic findings and the extent of myocardial scar contribute to risk assessment.
Management
Follow-up focuses on symptoms, rhythm burden and ventricular function. High-intensity endurance exercise may accelerate disease in susceptible patients and should be discussed with a specialist. Medicines, catheter ablation and an implantable cardioverter defibrillator may be considered according to the individual arrhythmic risk; ablation does not remove the underlying disease.
First-degree relatives may need structured cardiac screening and genetic counselling.
Clinical Depth and Risk Assessment
Risk is not defined by the diagnostic label alone. Symptoms, ECG and rhythm findings, ventricular function, myocardial scar or structural change, family history, associated disease and previous events are integrated. Genetic results, when relevant, require expert interpretation; a variant of uncertain significance is not equivalent to a diagnosis.
Diagnostic Strategy and Limitations
Testing is selected to answer a specific question. ECG, ambulatory monitoring, echocardiography, cardiac MRI, CT, laboratory testing, exercise assessment or invasive evaluation have complementary roles. A normal test may not exclude an intermittent disorder, while an abnormal measurement must be checked against technical quality and clinical probability.
Treatment Decision Framework
Treatment may combine risk-factor control, condition-specific medicines, rhythm or heart-failure therapy, catheter procedures, surgery and implanted devices. These options address different mechanisms and are not automatically substitutes for one another. Expected benefit, uncertainty, procedural burden and the patient’s informed preferences should be discussed explicitly.
Long-Term Follow-up
Follow-up assesses symptoms, exercise capacity, rhythm burden, ventricular function and treatment tolerance over time. Family screening may be appropriate in inherited or suspected inherited disease. New fainting, sustained rapid rhythm, chest pain, neurological symptoms or rapidly worsening breathlessness requires urgent assessment.
Questions to Discuss With the Cardiology Team
- Which finding has the greatest influence on my present risk?
- Which test or treatment would genuinely change management?
- What symptoms should lead to an earlier appointment or emergency care?
- Do relatives need clinical or genetic assessment?
Medical Information Note
This page supports an informed discussion with the clinical team. It does not provide a personal diagnosis, medicine dose or sports-clearance decision.